Dana Foresman

Dana Foresman

Auto-generated profile, based on publicly available information

Dana Foresman

Moffitt Cancer Center 1 Department of Immunology Tampa, Florida

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
HZHong Zheng
Hong Zheng
XYXiaoqing Yu
Xiaoqing Yu
MIMohammed L. Ibrahim
Mohammed L. Ibrahim
DFDana Foresman
Dana Foresman
MXMengyu Xie
Mengyu Xie
ABAmer A. Beg
Amer A. Beg
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.